接受初始伊马替尼治疗的慢性期慢性髓性白血病患者分子学反应的预测评分系统
研究基于1369例连续接受初始伊马替尼治疗的慢性期慢性髓性白血病(CML)患者数据,随机分为训练集(n=913)和验证集(n=456)。男性、较高白细胞浓度、较低血红蛋白浓度、较高外周血原始细胞百分比和较大脾脏尺寸与MMR和MR4累积发生率较低显著相关。利用Fine-Gray模型开发了预测MMR和MR4的评分系统,将患者分为低、中、高危组,在训练集和验证集中均显示出良好的预测区分度和准确性,具有较高的AUROC值。
要点
- 男性、高白细胞、低血红蛋白、高外周血原始细胞及大脾脏与较低的MMR和MR4累积发生率显著相关。
- 基于Fine-Gray模型建立的评分系统可将患者分为低、中、高危三组,各组MMR和MR4累积发生率显著不同。
- 评分系统在训练集和验证集中均表现出良好的预测区分度和准确性,AUROC值较高。
核心结论
- 这些数据可能有助于医生决定初始伊马替尼治疗的适当性。
研究设计与样本
- 研究分析了1369例连续接受初始伊马替尼治疗的慢性期CML患者的数据,随机分配至训练集(n=913)和验证集(n=456)。
主要发现
- 在训练集中,男性、较高白细胞浓度、较低血红蛋白浓度、较高外周血原始细胞百分比和较大脾脏尺寸与较低的MMR和MR4累积发生率显著相关。
- 利用Fine-Gray模型开发的预测评分系统将患者分为低、中、高危组,各组MMR和MR4累积发生率显著不同。
- 评分系统在训练集和验证集中均具有良好的预测区分度和准确性,AUROC值较高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is vital for physicians and persons with chronic myeloid leukemia (CML) to accurately predict the likelihood of achieving a major molecular response (MMR) and a deep molecular response (DMR; at least MR4) at the start of imatinib-therapy, which could help in decision making of treatment goals and strategies. To answer this question, we interrogated data from 1369 consecutive subjects with chronic phase CML receiving initial imatinib-therapy to identify predictive co-variates. Subjects were randomly-assigned to training (n = 913) and validation (n = 456) datasets. Male sex, higher WBC concentration, lower haemoglobin concentration, higher percentage blood blasts and larger spleen size were significantly-associated with lower cumulative incidences of MMR and MR4 in training dataset. Using Fine-Gray model, we developed the predictive scoring systems for MMR and MR4 which classified subjects into the low-, intermediate- and high-risk cohorts with significantly-different cumulative incidences of MMR and MR4 with good predictive discrimination and accuracy in training and validation cohorts with high area under the receiver-operator characteristic curve (AUROC) values. These data may help physicians decide appropriateness of initial imatinib therapy.
引用
- Zhang XS, Gale RP, Li ZY, et al. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022. PMID: 35650426. doi:10.1038/s41375-022-01616-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。